<DOC>
	<DOC>NCT01459224</DOC>
	<brief_summary>Patients who are newly diagnosed with Hodgkin's lymphoma will undergo disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo an extended MRI scan.</brief_summary>
	<brief_title>MELT - MRI Evaluation of Lymphoma Treatment</brief_title>
	<detailed_description>The trial will be a single centre cohort study in patients newly diagnosed with Hodgkin's lymphoma undergoing disease staging at diagnosis and initial treatment response assessment. At each time point (initial staging and treatment response assessment) in addition to standard imaging investigations (PET CT, Chest CT, anatomical MRI of the abdomen and pelvis and abdominal USS), patients will undergo advanced anatomical and functional MRI sequences.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Aged 5 to 20 years (inclusive) with participant and parent/guardian informed consent Histologically confirmed first presentation of Hodgkin's Lymphoma Either entered into the Euronet PHLC1 trial or LP1 trials OR not formally entered into the Euronet trials but treated on the chemotherapy regimens of the Euronet trials for classical and lymphocyte predominant Hodgkin Lymphoma Contraindications to MRI (e.g. pacemaker) Previous malignancy or previous chemotherapy or radiotherapy treatment for malignancy Pregnancy or nursing</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>